The global market for peptide therapeutics market derives much of its demand from the treatment of cancer and diabetes. The rising incidence of these diseases is making way for the advancement of peptide drugs, which in turn is propelling the global peptide therapeutics market. Additionally, the technical advancements in peptide drugs have resulted in a reduction in total production cost, fueling the production process of new peptide drugs.
Browse Full Global Peptide Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
On the other hand, API manufacturers are facing a tough challenge from the complex structure of peptides. Other than this, the lack of regulatory standards to arbitrate developments in peptide drugs is also hampering the growth of the peptide therapeutics market. However, biotech enterprises are identifying prospects for future growth in collaboration with major pharmaceutical firms across the globe.The global peptide therapeutics market is expected to expand at a CAGR of 2.8% during the period from 2014 to 2020 in order to reach US$23.7 billion by 2020. The market had reached a value of US$18.9 billion in 2013.
Market for Respiratory Disorders Poised to Grow at Highest CAGR between 2014 and 2020
Peptide therapeutics find application in the treatment of various kinds of ailments such as cardiovascular, nervous, gastrointestinal, respiratory, metabolism-related, in addition to cancer, various infections, and pain. The cancer market was the dominant application segment of the peptide therapeutics market in 2013. However, the respiratory disorder market segment is projected to develop at the highest CAGR during the period from 2014 to 2020 owing to the recent approval of lucinactant, sold under the brand name Surfaxin.
The global peptide therapeutics market is analyzed on three fronts: Route of administration, marketing status, and regional distribution of the global...